Wednesday, July 8, 2026

pharma · Colon Carcinoma Metastatic in the Liver · Metastatic Melanoma · VCNX

Vaccinex

Vaccinex is a pharma organization headquartered in Rochester, USA. It trades on NYSE under ticker VCNX. Primary therapeutic focus areas include Colon Carcinoma Metastatic in the Liver, Metastatic Melanoma, Metastatic Pan

1895 Mt Hope Ave, Rochester, New York 14620, US HQ
28 Employees
Public company Type
VCNX · NYSE Ticker
Company details
Status
Public
HQ
1895 Mt Hope Ave, Rochester, New York 14620, US
Employees
28
Programs
11
Drugs
8
Patents
41
Clinical program

VX15/2503 + avelumab

Phase 2 · small molecule · Carcinoma, Non-Small-Cell Lung

VX15/2503 + avelumab for Carcinoma, Non-Small-Cell Lung is a Phase 2 program (small_molecule) at VACCINEX, INC. with 1 ClinicalTrials.gov record(s).

← All VACCINEX, INC. projects Phase 2 small molecule completed

Internal code VX15/2503-04

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
VACCINEX, INC.
Phase
Phase 2
Modality
small_molecule
Indication
Carcinoma, Non-Small-Cell Lung
Status
completed
Trials
1